Summary
The pharmacokinetics of the ß1-selective adrenergic antagonist (R,S)-celiprolol has been studied after oral administration of 200 mg celiprolol-HCl to 8 healthy volunteers and 8 patients with various degrees of impaired renal function.
No significant difference was found between the two enantiomers in the control group or in the patients. In healthy volunteers an average of 9.8% of the dose of R-(+)-celiprolol and 9.5% of S-(-)-celiprolol was recovered unchanged in the urine. Renal impairment reduced the urinary excretion of both enantiomers to the same extent according to the severity of the uraemia, producing higher AUCs. Nevertheless, the terminal half-lives of the R- and S-enantiomers were not significantly different between the groups. Dosage reduction in patients with renal impairment does not seem to be necessary.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Hitzenberger G, Takacs F, Pittner H (1983) Pharmakokinetik des β-Rezeptorenblockers Celiprolol nach einmaliger intravenöser und oraler Gabe am Menschen. Drug Res 33: 50–52
Schmidt P, Takacs F, Pittner H, Minar E, Balcke P, Zazgornik J, Deutsch E (1985) Vergleichende Pharmakokinetik des β1-Rezeptorenblockers Celiprolol nach oraler Einzelgabe an Nierengesunde und an Patienten mit eingeschränkter Nierenfunktion. Wien Klin Wochenschr 97: 729–732
Norris RJ, Lee EH, Muirhead D, Sanders SW (1986) A pharmacokinetic evaluation of celiprolol in healthy elderly volunteers. J Cardiovasc Pharmacol 8: 91–92
Riddell JG, Harron DWG, Shanks RG (1987) Clinical pharmacokinetics of β-adrenoceptor antagonists — an update. Clin Pharmacokinet 12: 305–320
Riddell JG, Shanks RG, Brogden RN (1987) Celiprolol — a preliminary review of its pharmacodynamic and pharmacokinetic properties and its therapeutic use in hypertension and angina pectoris. Drugs 34: 438–458
Gluth WP, Sörgel F, Geldmacher v Mallinckrodt M (1983) Celiprolol kinetics in healthy volunteers after oral dosing. Naunyn-Schmiedebergs Arch Pharmacol 324 [Suppl]: R77 (Abstract no 308)
Rameis H (1984) Neue, in Österreich registrierte Spezialitäten. Wien Klin Wochenschr 96: 299–302
Wolf PS, Smith RD, Khandwala A, Inwegen RG van, Gordon RJ, Mann WS, Romano DV, Pruss TP (1985) Celiprolol — pharmacological profile of an unconventional β-blocker. Br J Clin Pract 39 [Suppl 40]: 5–11
Hartmann C, Krauss D, Spahn H, Mutschler E (1989) Simultaneous determination of (R)- and (S)-celiprolol in human plasma and urine: high-performance liquid chromatographic assay on a chiral stationary phase with fluorimetric detection. J Chromatogr 496: 387–396
Caruso FS, Doshan HD, Hernandez PH, Costello R, Applin W, Neiss ES (1985) Celiprolol: pharmacokinetics and duration of pharmacodynamic activity. Br J Clin Pract 39: 12–16
Author information
Authors and Affiliations
Additional information
Part of the Ph.D. thesis of Claudia Hartmann
Rights and permissions
About this article
Cite this article
Hartmann, C., Frölich, M., Krauß, D. et al. Comparative enantioselective pharmacokinetic studies of celiprolol in healthy volunteers and patients with impaired renal function. Eur J Clin Pharmacol 39, 573–576 (1990). https://doi.org/10.1007/BF00316098
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00316098